journal article·2024-12-18

Delayed Magnetic Resonance Imaging of Alzheimer’s Disease by Using Poly(2-(methacryloyloxy)ethyl phosphorylcholine)-Functionalized Nanoprobes

Wenyue Li, Xinyi Zhang, Chuang Liu, Yuqiang Ma, Yanjiao Jiang, Ni Zhang, Yi Hou

ACS Applied Materials & Interfaces· Volume 16· Issue 50
Publisher page

Abstract

Alzheimer’s disease (AD) is one of the most common neurodegenerative diseases, commonly affecting the aged, with pathophysiological changes presenting 15 to 20 years before clinical symptoms. Early diagnosis and intervention are crucial in effectively slowing the progression of AD. In the current study, poly(2-(methacryloyloxy)ethyl phosphorylcholine) (PMPC)-functionalized NaGdF 4 nanoparticles (NaGdF 4 –PMPC) were developed as magnetic resonance imaging (MRI) contrast agents for targeting alpha 7 nicotinic acetylcholine receptors (α7 nAChRs) in AD mice. NaGdF 4 –PMPC showed excellent biocompatibility, targeting ability, and MRI performance, with the longitudinal molar relaxivity ( r 1 ) and transverse molar relaxivity ( r 2 ) being 1.21-fold and 1.33-fold higher than those of the clinical contrast agent Gd-DTPA, respectively, resulting in higher-sensitive MR angiography. After intravenous injection, 3D dynamic contrast-enhanced (DCE) MR images with high-resolution vasculature of the mouse brain were obtained. In addition, by using NaGdF 4 –PMPC, susceptibility-weighted imaging (SWI) signals in AD mouse brains were greatly retained compared to those in healthy mice for 24 h, emphasizing the excellent targeting ability of NaGdF 4 –PMPC. Furthermore, the CD31, α7 nAChRs, and Thioflavin S staining were also utilized to investigate the relationship among vascular inflammation, α7 nAChRs, and amyloid-β (Aβ) deposition in AD mice. This work highlights a promising targeted imaging strategy for the timely diagnosis of AD.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Neurological Disease Mechanisms and Treatments · Neurological Disorders and Treatments · Alzheimer's disease research and treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

College of Materials Science and Engineering, and College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China

Department of Psychiatry, and Center for Preclinical Safety Evaluation of Drugs, West China Hospital of Sichuan University, Chengdu 610041, China

Funding

Natural Science Foundation of Beijing Municipality · National Natural Science Foundation of China

References (35)

Show source-provided references
1. 10.1016/j.pharep.2014.09.00410.1016/j.pharep.2014.09.004 ↗
2. 10.1002/alz.1263810.1002/alz.12638 ↗
3. 10.1016/j.jalz.2011.03.00310.1016/j.jalz.2011.03.003 ↗
4. 10.1016/S1474-4422(07)70178-310.1016/S1474-4422(07)70178-3 ↗
5. 10.1016/S1474-4422(17)30159-X10.1016/S1474-4422(17)30159-X ↗
6. 10.1016/j.jalz.2011.03.00510.1016/j.jalz.2011.03.005 ↗
7. 10.1056/NEJMoa080614210.1056/NEJMoa0806142 ↗
8. 10.1212/01.wnl.0000228230.26044.a410.1212/01.wnl.0000228230.26044.a4 ↗
9. 10.1016/S0140-6736(20)32205-410.1016/S0140-6736(20)32205-4 ↗
10. 10.31887/DCNS.2009.11.2/cqiu10.31887/DCNS.2009.11.2/cqiu ↗
11. 10.1001/archneur.59.11.173710.1001/archneur.59.11.1737 ↗
12. 10.1155/2012/64635410.1155/2012/646354 ↗
13. 10.3389/fnagi.2015.0012410.3389/fnagi.2015.00124 ↗
14. 10.1038/nm.391310.1038/nm.3913 ↗
15. 10.3389/fnagi.2021.81121010.3389/fnagi.2021.811210 ↗
16. 10.1093/eurheartj/ehac544.305410.1093/eurheartj/ehac544.3054 ↗
17. 10.1016/j.jcis.2024.09.02010.1016/j.jcis.2024.09.020 ↗
18. 10.1016/j.jcis.2021.12.07110.1016/j.jcis.2021.12.071 ↗
19. 10.1186/s40824-022-00275-510.1186/s40824-022-00275-5 ↗
20. 10.1186/s12951-024-02732-w10.1186/s12951-024-02732-w ↗
21. 10.1002/EXP.2023016310.1002/EXP.20230163 ↗
22. 10.1002/adma.20180755710.1002/adma.201807557 ↗
23. 10.1002/mabi.20200039210.1002/mabi.202000392 ↗
24. 10.3233/jad-2008-1540110.3233/jad-2008-15401 ↗
25. 10.1021/acs.analchem.4c0109710.1021/acs.analchem.4c01097 ↗
26. 10.1126/sciadv.adq408210.1126/sciadv.adq4082 ↗
27. 10.2147/IJN.S25239710.2147/IJN.S252397 ↗
28. 10.1002/anie.20110087510.1002/anie.201100875 ↗
29. 10.1021/acsnano.4c0753310.1021/acsnano.4c07533 ↗
30. 10.1016/j.tins.2021.11.00610.1016/j.tins.2021.11.006 ↗
31. 10.2174/138161282266616012711291410.2174/1381612822666160127112914 ↗
32. 10.3390/molecules2709278010.3390/molecules27092780 ↗
33. 10.25259/IJPP_129_202010.25259/IJPP_129_2020 ↗
34. 10.1038/s41582-023-00792-410.1038/s41582-023-00792-4 ↗
35. 10.1002/glia.2332610.1002/glia.23326 ↗